Thompson Davis & Co., Inc. Tg Therapeutics, Inc. Transaction History

Thompson Davis & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 03, 2018	SELL	$12.5 - $15.0 $18,750 - $22,500	-1,500 Closed	0 $0
Q1 2018 May 02, 2018	BUY	$8.7 - $16.8 $2,175 - $4,200	250 Added 20.0%	1,500 $21,000
Q4 2017 Feb 05, 2018	SELL	$7.35 - $12.3 $13,097 - $21,918	-1,782 Reduced 58.77%	1,250 $10,000
Q2 2017 Aug 10, 2017	BUY	N/A	3,032	3,032 $30,000

349

89.5M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.61B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Thompson Davis & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on Thompson Davis & Co., Inc. with notifications on news.